Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Gene therapy ‘can cure lameness’ - study
The research team believe this gene therapy could offer a much faster healing time.
Research may also have implications for human medicine 

A ‘promising’ gene therapy could offer faster and more effective treatment for lameness in horses, scientists say.

An international team injected DNA into the tendons and ligaments of horses that were lame as a result of injury. Within two to three weeks, the horses were able to walk and trot, and after two months, they were back to full health, galloping and competing.

The results also showed that the tissue within the limbs had fully recovered. Twelve months after treatment, the horses were completely fit, active and pain free.

Scientists used a combination of the vascular endothelial growth factor gene (VEGF164), to enhance blood vessel growth, and the bone morphogenetic protein 2 (BMP2), which is important for bone and cartilage development.

Both genes were derived from horses and cloned into a single plasmid DNA, which is biologically safe and unlikely to provoke an immune reaction from the body.

The research team believe this gene therapy could offer a much faster healing time, whilst significantly reducing relapse rates. Current medical therapies have a relapse rate of 60 per cent. Even the best regenerative medicine treatments have a 20 per cent relapse rate and take five or six months to work.

Lead author Professor Albert Rizvanov, from Kazan Federal University, said: “Advancing medicine, relieving pain and restoring function were the main aims of this study. We have shown that these are possible and within a much shorter time span than treatments available at the moment.”

In addition, scientists reported that no side effects or adverse reactions were seen in the horses who received treatment.

These findings not only have implications for veterinary medicine, they could also advance treatments for humans. Scientists say this type of therapy could be used in other injuries and situations, ranging from fertility problems to spinal cord injuries.

Dr Catrin Rutland, who led the work at University of Nottingham, said: “This pioneering study advances not only equine medicine but has real implications for how other species and humans are treated for lameness and other disorders in the future. The horses returned to full health after their injuries and did not have any adverse side effects. This is a very exciting medical innovation.”

The next step is to secure funding for a larger trial.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.